Aging, mild cognitive impairment, and Alzheimer's disease

Neurologic Clinics

Volumn 18, Issue 4, 2000, Pages 789-805

  Petersen, Ronald C ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DIAGNOSTIC APPROACH ROUTE; FAMILY HISTORY; HUMAN; LABORATORY TEST; LUMBAR PUNCTURE; MENTAL HEALTH; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEURORADIOLOGY; PRIORITY JOURNAL; RATING SCALE; REVIEW;

EID: 0034525923     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70226-7     Document Type: Article

References (116)

1. Cerebrospinal fluid tau and Abeta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
2. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
3. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer disease
4. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease
5. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
6. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
7. The role of lumbar puncture in the evaluation of dementia: The Durham Veterans Administration/Duke University Study
8. MRI of entorhinal cortex in mild Alzheimer's disease
9. Progression to dementia in patients with isolated memory loss
10. Neuropathological staging of Alzheimer-related changes
11. Psychiatric phenomena in Alzheimer's disease II: Disorders of perception
12. Psychiatric phenomena in Alzheimer's disease: IV. Disorders of behavior
13. Canadian Study of Health and Aging: Study methods and prevalence of dementia
14. The reversible dementias: Do they reverse?
15. Hippocampal atrophy in early Alzheimer's disease: Anatomic specificity and validation
16. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
17. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change: Report of a National Institute of Mental Health Work Group
18. Concepts of mild memory impairment in the elderly and their relationship to dementia: A review
19. Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type
20. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid
21. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease
22. Hippocampal formation atrophy: Prognostic significance for Alzheimer's disease
23. The radiologic prediction of Alzheimer's disease: The atrophic hippocampal formation
24. Selective medial and lateral temporal lobe pathology in cases at risk for AD: Diagnostic role of PET
25. Identification of normal and pathological aging in prospectively studied nondemented elderly humans
26. The US economic and social costs of Alzheimer's disease revisited
27. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
28. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported
29. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium
30. The prevalence and 3-year incidence of dementia in older black and white community residents
31. Dementia: Evaluation and diagnosis
32. A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease
33. Mild cognitive impairment in the elderly: Predictors of dementia
34. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician
35. Mild cognitive impairment raises Alzheimer's disease risk
36. Clinical-neuropathological correlations in Alzheimer's disease and related dementias
37. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
38. Assessment CSF levels of tau protein in mildly demented patients with Alzheimer's disease
39. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis
40. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease
41. Cortical localization of working memory
42. Working memory and the mind
43. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state: The Kame Project
44. Biomarkers of Alzheimer's disease
45. The apolipoprotein E polymorphism: A comparison of allele frequencies and effects in nine populations
46. Age-specific incidence of Alzheimer's disease in a community population
47. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans
48. Evidence of early vulnerability of the medial and inferior aspects of the temporal lobe in an 82 year old patient with preclinical signs of dementia
49. Atherosclerosis apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
50. The scintigraphic appearance of Alzheimer's disease: A prospective study using technetium-99m-HMPAO SPECT
51. A new clinical scale for the staging of dementia
52. Memory-related neural systems in Alzheimer's disease: An anatomical study
53. Mayo's Older Americans Normative Studies: WAIS-R, WMS-R, and AVLT norms for ages 56 to 97
54. Neuropsychological detection and characterization of preclinical Alzheimer's disease
55. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
56. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease
57. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
58. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
59. Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases
60. Quantitative brain SPECT in Alzheimer's disease and normal aging
61. The incidence of dementia: A meta-analysis
62. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan
63. Advances in the diagnosis of dementia: Accuracy of diagnosis and consequences of misdiagnosis of disorders causing dementia
64. The world-wide impact of dementia: Projections of prevalence and costs
65. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia
66. Incorrect diagnosis of Alzheimer's disease: A clinicopathologic study
67. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975
68. A short test of mental status: Description and preliminary results
69. Diagnostic accuracy of Alzheimer's disease: A neuropathological study
70. Senescent forgetfulness: Benign and malignant
71. The validity of 3 clinical diagnostic criteria for Alzheimer's disease
72. Diagnostic tests in the evaluation of dementia: A prospective study of 200 elderly outpatients
73. Age-associated cognitive decline
74. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons
75. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
76. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
77. Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging
78. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease
79. Prevalence of Alzheimer's disease and vascular dementia: Association with education
80. Incidence and risk of dementia: The Rotterdam Study
81. Neuropathologic substrate of mild cognitive impairment
82. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease
83. Mild cognitive impairment or "questionable dementia?"
84. Normal aging, mild cognitive impairment, and early Alzheimer's disease
85. Memory and MRI-based hippocampal volumes in aging and AD
86. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
87. Memory function in very early Alzheimer's disease
88. Aging, memory, and mild cognitive impairment
89. Mild cognitive impairment: Clinical characterization and outcome
90. Prevalence of Alzheimer's disease in a retirement community
91. Apolipoprotein E polymorphism and Alzheimer's disease
92. Report of the Quality Standards Subcommittee of the American Academy of Neurology: Practice parameter for diagnosis and evaluation of dementia
93. The Global Deterioration Scale for assessment of primary degenerative dementia
94. Incidence of dementia and Alzheimer's disease: A reanalysis of data from Rochester, Minnesota, 1975-1984
95. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease
96. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
97. The effect of pre-clinical dementia on estimates of normal cognitive function in aging
98. Age-associated memory impairment diagnoses: Problems of reliability and concerns for terminology
99. Definition, course and outcome of mild cognitive impairment
100. The investigation of dementia: Results in 200 consecutive admissions
101. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: Correlation to visual and verbal memory
102. Volumes of hippocampus and amygdala in the MRI-based diagnosis of early Alzheimer's disease
103. Influence of education and occupation on the incidence of Alzheimer's disease
104. Behavioral disturbances in dementia of the Alzheimer's type
105. Patients clinically assessed at an Alzheimer's Center generally have Alzheimer's pathology
106. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute of Aging Work Group: Consensus report of the working group on molecular and biochemical markers of the Alzheimer's disease
107. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinico-pathological study of 57 cases
108. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study
109. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment
110. Multicenter clinicopathological correlation in dementia
111. A neuroimaging in the diagnosis of Alzheimer's disease: Positron and single photon emission tomography
112. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures
113. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study
114. Overview of depression and psychosis in Alzheimer's disease
115. Usefulness of MRI measures of entorhinal cortex vs. hippocampus in AD